1. Home
  2. IMTX

as of 11-18-2026 10:27am EST

$6.32
+$0.02
+0.32%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Founded: N/A Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 992.8M IPO Year: 2020
Target Price: $15.97 AVG Volume (30 days): 1.0M
Analyst Decision: Strong Buy Number of Analysts: 9
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $6.06 - $12.41 Next Earning Date: 11-10-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -39.4% Revenue Growth (next year): 14.22%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Stock Insider Trading Activity of Immatics N.V. (IMTX)

IMTX Aug 26, 2026

Avg Cost/Share

$8.69

Shares

863,060

Total Value

$7,499,991.40

Owned After

11,246,516

SEC Form 4

Share on Social Networks: